tiprankstipranks
Trending News
More News >
Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
US Market

Nautilus Biotechnolgy (NAUT) Earnings Dates, Call Summary & Reports

Compare
132 Followers

Earnings Data

Report Date
Aug 05, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
-0.14
Last Year’s EPS
-0.14
Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings

Earnings Call Summary

Earnings Call Date:Apr 29, 2025
|
% Change Since: 4.41%
|
Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook. Nautilus Biotechnology reported significant advancements in their tau proteoform assay, cost efficiency leading to reduced expenses, and a strong cash position. There is enthusiastic interest from the research community and promising early results in Alzheimer’s research. However, the company did face some challenges, including a reduction in workforce and slower progress in forming pharmaceutical partnerships. Overall, the positive aspects, particularly in technological advancements and financial health, outweigh the lowlights.
Company Guidance
During the Nautilus Biotechnology, Inc. First Quarter 2025 Earnings Conference Call, the company provided guidance highlighting significant advancements in their proteomic platform development. The focus was on targeted proteoform detection and broad scale discovery, with the tau proteoform assay showing promising results in reproducibility, accuracy (with a median percent error of approximately 10%), and dynamic range, exceeding expectations by a factor of three. They reported a 13% decrease in total operating expenses year-over-year, with research and development expenses at $11.5 million and a net loss of $16.6 million. The company anticipates launching their platform in late 2026 and projects their cash runway to extend through 2027, with $193 million in cash and equivalents at the end of Q1 2025. Nautilus is in discussions for potential partnerships, particularly in academic and nonprofit sectors, to further validate and demonstrate the platform's capabilities.
Successful Tau Proteoform Assay Validation
The assay's reproducibility, accuracy, dynamic range, and sample compatibility aligned with launch specifications. Median percent error was approximately 10%, exceeding the target by a factor of three, and the median coefficient of variation was more than 15 times better than the target.
Cost Efficiency and Expense Reduction
Total operating expenses for Q1 2025 were $18.8 million, a 13% decrease compared to $21.6 million in Q1 2024. The reduction in expenses is due to cost efficiency and absence of nonrecurring costs from 2024.
Strong Cash Position
Nautilus ended the quarter with approximately $193 million in cash, cash equivalents, and investments, with a projected cash runway through 2027.
Positive Customer Feedback and Interest
Significant interest from proteomics researchers and potential partners in both targeted proteome and broad-scale discovery capabilities of Nautilus's platform.
Promising Alzheimer’s Disease Research
Early studies using the tau proteoform assay showed new insights into complex phosphorylation patterns in Alzheimer’s disease.

Nautilus Biotechnolgy (NAUT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

NAUT Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 05, 2025
2025 (Q2)
-0.14 / -
-0.14
Apr 29, 2025
2025 (Q1)
-0.15 / -0.13
-0.1513.33% (+0.02)
Feb 27, 2025
2024 (Q4)
-0.15 / -0.14
-0.140.00% (0.00)
Oct 29, 2024
2024 (Q3)
-0.17 / -0.13
-0.130.00% (0.00)
Jul 30, 2024
2024 (Q2)
-0.16 / -0.14
-0.13-7.69% (-0.01)
Apr 30, 2024
2024 (Q1)
-0.16 / -0.15
-0.12-25.00% (-0.03)
Feb 28, 2024
2023 (Q4)
-0.16 / -0.14
-0.11-27.27% (-0.03)
Oct 31, 2023
2023 (Q3)
-0.15 / -0.13
-0.11-18.18% (-0.02)
Aug 02, 2023
2023 (Q2)
-0.15 / -0.13
-0.12-8.33% (-0.01)
May 02, 2023
2023 (Q1)
-0.16 / -0.12
-0.137.69% (+0.01)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

NAUT Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 29, 2025
$0.68$0.73+7.35%
Feb 27, 2025
$1.43$1.17-18.18%
Oct 29, 2024
$2.81$2.77-1.42%
Jul 30, 2024
$2.74$2.67-2.55%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Nautilus Biotechnolgy (NAUT) report earnings?
Nautilus Biotechnolgy (NAUT) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
    What is Nautilus Biotechnolgy (NAUT) earnings time?
    Nautilus Biotechnolgy (NAUT) earnings time is at Aug 05, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is NAUT EPS forecast?
          NAUT EPS forecast for the fiscal quarter 2025 (Q2) is -0.14.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis